Document:

<PAGE>

                                                                 EXHIBIT 10.15

                                  BIOMEDICINES

23 November 1999

PERSONAL AND CONFIDENTIAL

Curtis L. Scribner, M.D.
3708 Stewart Drwy.
N. Chevy Chase, MD 20815-4731
Tel: 301-656-2249 (home)

Dear Doctor Scribner:

On behalf of the Board of Directors of BioMedicines, Inc. (the "Company"), I
would like to offer you the position of Vice President Regulatory Affairs. In
this capacity you will report to me.

In your role as Vice President Regulatory Affairs, you will have principal
responsibility for planning and directing the regulatory activities for all
Company projects and for:

-    establishing a regulatory affairs infrastructure that is both
     cost-effective and appropriate to the Company's needs at any given time
-    the hiring and subsequent management of personnel in your group(s)
-    selecting and managing external vendors for those projects whose regulatory
     aspects are performed in whole or in part externally
-    evaluating potential product acquisitions for the Company
-    participating in partnering discussions, for in- or out-licensing
-    contributing to safety management practices and activities for the Company
-    helping to ensure compliance with good scientific practices in all areas
     for which you are responsible or to which you may contribute
-    accurate and timely budgetary planning and execution.

In your role as Vice President you will also be a member of the Company's Senior
Management Team with joint responsibility for recommending Company strategy to
the Board as well as setting Company policies.

The Board has also directed me to indicate to you its particular desire that you
will contribute creatively, constructively and cordially to the success of your
colleagues and fellow members of the Senior Management Team. I share this view
regarding the importance of such cooperative activities and would indicate that
the Board also believes that all Company officers should be evaluated on the
basis of both individual and cooperative achievements. I think that you will
influence every aspect of developmental and commercial activities for the
Company. I believe that your contributions to your colleagues in Development
will be singularly influential.

This letter will serve to confirm the terms of your employment with
BioMedicines, such employment to begin on 17 January 2000 or earlier, by mutual
agreement. If the terms discussed below are acceptable to you, please sign this
confirmation letter where indicated and return it to me, retaining a copy for
your records.

                                       1.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 2

1.   COMPENSATION.

     (a)  SALARY, PERFORMANCE BONUS EXPENSE REIMBURSEMENTS, SIGN-ON BONUS,
MOVING ALLOWANCE AND HOME LOAN. You will be paid a monthly salary of $16,250.00.
You will be eligible for a cash bonus of up to twenty percent (20%) of your
annual base pay. Changes in base pay or the payment of bonuses are made at the
discretion of the Board upon receipt of recommendations from the Compensation
Committee. Currently, salary payments are made twice a month. In addition, all
reasonable business expenses will be reimbursed so long as they are incurred in
the ordinary course of business and consistent with the then-applicable Company
policies.

A one-time moving expense allowance of $20,000 will be paid. A one-time sign-on
bonus of $40,000 will also be paid if you respond favorably to this offer within
seven (7) days of receiving same. Should you not remain an employee for at least
12 months, however, the sign-on bonus and moving expense allowance must be
repaid to the company prorata at the rate of 1/12th of the total of $60,000 for
each partial or full month of service less than 12 months.

The company will provide to you on a one-time basis a loan of up to one hundred
twenty-five thousand dollars ($125,000) with a term of one year and at an
interest rate of the prevailing rate for fixed-rate, first mortgages at the time
of the loan. Payments on the loan shall be due monthly. However, each interest
payment shall be forgiven when due subject to continued satisfactory employment
with the Company. In addition, in the event that the unpaid principal balance
shall not be otherwise due and payable at the end of the first one-year term,
then the loan may be extended for a second one-year period subject, however, to
continued satisfactory employment with the Company. The loan shall be secured
with a second mortgage on the property that you may choose to acquire. Only the
original first mortgage may be senior to this second mortgage held by the
Company, and the sum of the amount of the first mortgage and the actual amount
of the loan from the Company may not exceed the purchase price of the property
purchased using the loan from the Company. The unpaid principal balance of this
loan shall be due and payable

-    sixty (60) days from the date that you sell your current residence;
-    sixty (60) days from the date that you voluntarily cease to be a full-time
     employee of the Company or are dismissed for cause;
-    upon the sale of the property on which the second mortgage is held by the
     Company; or
-    in the event that you declare personal bankruptcy.
Other terms and conditions typical for such loans may also apply.

     (b)  STOCK OPTIONS. It will be recommended that you receive an option to
purchase up to one hundred thirty thousand (130,000) shares of common stock,
such number and related purchase price to be formally approved by the Board of
Directors at the sole discretion of the Board.

It is anticipated that eighty thousand (80,000) shares of this grant, if
approved, will vest at the rate of approximately 2.083% per month (i.e., 25% per
year), subject to the condition that vesting

                                       2.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 3

for the first 12 months will occur only after you have satisfactorily completed
12 months of employment (i.e., options on 20,000 shares will vest only on the
first anniversary of your employment). Thereafter, vesting will occur monthly as
noted above. Options on these eighty thousand shares shall be identified as
"time-based options."

It is anticipated that up to fifty (50,000) thousand shares will become eligible
for vesting according to the following general schedule*:

-    substantive contribution to a successful United States (U.S.)
     Investigational New Drug Application (IND) filing defined as regulatory
     approval to begin clinical testing - 5,000 shares
-    substantive contribution to drug development such that the Board approves
     the initiation of phase III testing in the United States - 5,000 shares
-    substantive contribution to the acceptance of a U.S. New Drug Application
     (NDA) for filing - 15,000 shares
-    substantive contribution to the approval of a U.S. NDA - 20,000 shares
-    inventing a new use for a product such that a new patent application is
     filed in the United States and assigned to Company - 10,000 shares
-    co-inventing with another Company employee a new use for a product such
     that a new patent application is filed in the United States and assigned to
     Company - 5,000 shares
-    issuance of a U.S. patent assigned to the Company and for which you are an
     inventor - 10,000 shares
-    for patent applications or patents it is understood that such grants will
     apply only once per invention
-    identifying a new product licensing opportunity and then contributing
     substantially to the inlicensing of said product into the Company's
     portfolio - 25,000 shares

Options on these fifty thousand shares shall be identified as "event-based
options."

* Upon achievement of the goals stated above, vesting shall be made retroactive
to the date of your initial full-time employment with the Company.

The strike price of both the time-based and event-based options shall be $0.225
per share.

In the event that, outside the U.S., the equivalent of a U.S. IND is filed,
phase III testing begins, a marketing application is filed or approved, then 50%
of the number of shares identified above shall become eligible for vesting with
the remaining 50% becoming eligible when the related event occurs in the U.S.

Other terms, or terms that become applicable after the date of this letter, will
appear either in the BioMedicines Stock Option Plan of which you will receive a
copy in the event you accept this offer or in a separate communication to you
from the Company.

Please note that in the event of a stock split or "reverse split" the number of
options and the option price may be adjusted.

                                       3.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 4

Subject to the sole discretion of the Board, you may also be eligible to receive
additional options from time to time during your continued satisfactory
employment with the Company. In this event, the number of options and any
conditions of the grant(s) shall be communicated to you.

     (c)  HEALTH BENEFITS. Health insurance coverage for you will be provided
under the Company's group health plan. You will be entitled to all health and
medical benefits as are provided to other employees. In addition, you will be
entitled to participate in the Company's 401k plan and all other sponsored
employee benefit plans as and when they are adopted by BioMedicines.

     (d)  VACATION, HOLIDAYS AND SICK LEAVE. You will receive three (3) weeks of
paid vacation per year as described in the Company's Policy Manual. You are
encouraged to plan for and to take, under appropriate circumstances, the
vacation time to which you are entitled. Sick leave and holidays will be
provided in accordance with the Company's policies, which will be announced from
time to time.

2.   TERMINATION. You or the Company may terminate the employment relationship
at any time, for any reason, with or without good cause.

3.   NON-COMPETE REQUIREMENTS AND OUTSIDE ACTIVITIES. You agree that, while
serving as an employee of the Company, you will not engage in any activity which
is competitive with the Company and will give your sole and only loyalty to the
Company. It is understood that buying and selling of securities of any public
company does not constitute a violation of this agreement. An investment in a
private company other than, or not affiliated with, the Company may be construed
as a violation of this non-compete clause unless you have received the prior
approval of the Board of Directors or Chief Executive Officer of the Company, as
appropriate. It is understood that any reasonable obligations that you may have
to assist or cooperate with a previous employer in legal proceedings, in the
issuance of patents or prosecution of patent applications, or in compliance with
requests from governmental authorities do not constitute violations of this
agreement, provided that these obligations are not fulfilled on Company time and
do not adversely impact in a material way the performance of your current duties
to the Company.

4.   PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT. Your acceptance of this
offer is contingent upon the execution of the Company's Proprietary Information
and Inventions Agreements, copies of which are enclosed for your review and
execution.

5.   ARBITRATION. Any controversy between the parties hereto involving the
construction or application of any terms, covenants or conditions of this
Agreement, or any claims arising out of or relating to this Agreement or the
breach thereof or with your employment with the Company or any termination of
that employment, except with respect to prejudgment remedies, will be submitted
to and settled by final and binding arbitration in San Francisco, California, in
accordance with the Model Employment Dispute Resolution Rules of the American
Arbitration Association (the "Rules") then in effect, any arbitrator shall be
selected pursuant to such Rules

                                       4.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 5

and judgment upon the award rendered by the arbitrators may be entered in any
court having jurisdiction thereof.

Please note that the offer is conditional until proof of eligibility for
employment in California according to all applicable local, state, and federal
laws.

To accept this offer, please sign in the space below within seven (7) days of
the date of this offer, indicating your acceptance and agreement to the terms
contained herein. No amendment or modification of the terms of this letter will
be valid unless made in writing and signed by you and an authorized officer of
the Company.

On a personal note, I've enjoyed talking with you and believe that your
broad-based skills will significantly affect how we proceed day-to-day and long
term. I also believe that I will be able to turn to you for creative problem
solving, and I am particularly confident that your negotiating skills will help
everyone.

It is my hope that you will accept this offer and take a leading role in the
management of BioMedicines.

                                Yours, sincerely

                                Mark Moran, M.D.
                                Chief Executive Officer

Accepted by:

/s/ Curtis L. Scribner
----------------------------
Curtis Scribner, M.D.

November 26, 1999
----------------------------
Date

                                       5.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 6

                PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

23 November, 1999

BioMedicines, Inc.
1301 Marina Village Parkway Suite 200
Alameda, CA 94501

Gentlemen:

The Following confirms an agreement between me and BioMedicines, Inc., a
Delaware corporation (the "Company," which term includes the Company's
subsidiaries, successors and assigns), which is a material part of the
consideration for my employment by the Company:

1.   "Proprietary Information" is information that was or is developed by,
became or becomes known by, or was or is assigned or otherwise conveyed to the
Company, and which has commercial value in the Company's business. Proprietary
Information includes, without limitation, trade secrets, financial information,
product plans, customer lists, marketing plans and strategies, forecasts and
other business information, improvements, inventions, business strategies,
formulas, product ideas, works of authorship, processes, copyrightable or
patentable material, schematics, biological material (including cell lines,
antibodies, c-DNAs, antisense nucleotides, proteins, vectors, new chemical
entities, media, reagents and related materials) and techniques for their
handling and use, computer programs, algorithms, techniques, schematics,
know-how and data, and any other confidential or proprietary information of the
Company or its customers or clients which I have been, or may be exposed to, or
have learned or may learn of from time to time in connection with or as a result
of my capacity as a consultant to the Company or during the term of this
Agreement. Proprietary Information shall not include information that is through
no improper action or inaction by me, generally available to the public. I
understand that my employment creates a relationship of confidence and trust
between me and the Company with respect to Proprietary Information of the
Company or its customers which may be learned by me during the period of my
employment.

2.   In consideration of my employment by the Company and the compensation
received by me from the Company from time to time, I hereby agree as follows:

     (a)  All Proprietary Information and all patents, copyrights, trade secret
rights, and other rights (including throughout, without limitation, any
extensions, renewals, continuations or divisions of any of the foregoing) in
connection therewith shall be the sole property of the Company. I hereby assign
to the Company any rights I may have or acquire in such Proprietary Information.
At all times, both during my employment by the Company and after its
termination, I will keep in confidence and trust and will not use or disclose
any Proprietary Information or anything relating to it without the written
consent of the Company, except as may be necessary in the ordinary course of
performing my duties to the Company.

                                       6.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 7

     (b)  In the event of the termination of my employment by me or by the
Company for any reason, I shall return all documents, records, apparatus,
equipment and other physical property, or any reproduction of such property,
whether or not pertaining to Proprietary Information, furnished to me by the
Company or produced by myself or others in connection with my employment, to the
Company immediately as and when requested by the Company.

     (c)  I will promptly disclose to the Company, or any persons designated by
it, all "Inventions," which includes all improvements, inventions, formulas,
ideas, works of authorship, processes, computer programs, algorithms,
techniques, schematics, know-how and data, whether or not patentable, made or
conceived or reduced to practice or developed by me, either alone or jointly
with others, during the term of my employment and for three (3) months
thereafter. To the extent the Company does not have rights therein hereunder,
such disclosure shall be received by the Company in confidence and does not
extend the assignment made in Section (e) below.

     (d)  During the term of my employment and for one (1) year thereafter, I
will not encourage or solicit any employee of the Company to leave the Company
for any reason or to devote less than all of any such employee's efforts to the
affairs of the Company, provided that the foregoing shall not affect any
responsibility I may have as an employee of the Company with respect to the bona
fide hiring and firing of Company personnel.

     (e)  I agree that all Inventions which I make, conceive, reduce to practice
or develop (in whole or in part, either alone or jointly with others) during my
employment shall be the sole property of the Company to the maximum extent
permitted by Section 2870 of the California Labor Code, a copy of which is
attached herewith, and to the extent permitted by law shall be "works made for
hire." The Company shall be the sole owner of all patents, copyrights, trade
secret rights, and other intellectual property or other rights in connection
therewith. I hereby assign to the Company any rights I may have or acquire in
such Inventions. I agree to perform, during and after my employment, all acts
deemed necessary or desirable by the Company to permit and assist it, at the
Company's expense, in obtaining and enforcing patents, copyrights, trade secret
rights or other rights on such Inventions and/or any other Inventions I have or
may at any time assign to the Company in any and all countries. Such acts may
include, but are not limited to, execution of documents and assistance or
cooperation in legal proceedings. With respect to any and all matters arising
out of or relating to my employment or consultancy with the Company, I hereby
irrevocably designate and appoint the Company and its duly authorized officers
and agents, as my agents and attorneys-in-fact to act for and in my behalf and
instead of me, to execute and file any applications or related filings and to do
all other lawfully permitted acts to further the prosecution and issuance of
patents, copyrights, trade secret rights or other rights thereon with the same
legal force and effect as if executed by me.

     (f)  I attach hereto a complete list of all Inventions or improvements to
which I claim ownership and/or that I desire to remove from the operation of
this Agreement, and I covenant that such list is complete. If no such list is
attached to this Agreement, I represent that I have no such Inventions and
improvements at the time of signing this Agreement. I understand that any such
list shall not contain information that breaches an obligation of
confidentiality with a former employer.

                                       7.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 8

     (g)  I represent that my performance of all the terms of this Agreement
will not breach any agreement or obligation to keep in confidence proprietary
information acquired by me in confidence or in trust prior to my employment by
the Company. I have not entered into, and I agree I will not enter into, any
agreement either written or oral in conflict herewith or in conflict with my
employment with the Company.

3.   In consideration of the foregoing, the Company agrees that it will not
request as part of my employment that I divulge or make use of confidential
information of any of my former employers that has commercial value to the
former employer who developed such information.

4.   This Agreement shall be effective as of the first day of my employment by
the Company, and shall be binding upon me, my heirs, executors, assigns, and
administrators and shall inure to the benefit of the Company, its subsidiaries,
successors and assigns.

Accepted and Agreed to:

Dated: November 25, 1999
      -------------------------

/s/ Curtis L. Scribner                         By:  /s/ Mark Moran
-------------------------------                   -----------------------------
Curtis Scribner, M.D.                                 Mark Moran, M.D.
                                                      Chief Executive Officer
                                                      BioMedicines, Inc.

                                       8.
<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 9

                                    EXHIBIT A

1.   The following is a complete list of all inventions or improvements
relevant to the subject matter of my employment by BioMedicines, Inc. (the
"Company") that have been made or conceived or first reduced to practice by me
alone or jointly with others prior to my employment by the Company that I desire
to remove from the operation of the Company's Proprietary Information and
Inventions Agreement.

 X   No inventions or improvements.
---

2.   I propose to bring to my employment the following materials and documents
of a former employer:

 X   No materials or documents.
---

/s/ Curtis L. Scribner
------------------------------
Curtis Scribner, M.D.

<PAGE>

Curtis L. Scribner, M.D.
23 November 1999
Page 10

                                    EXHIBIT B

SECTION 2870. APPLICATION OF PROVISION PROVIDING THAT EMPLOYEE SHALL ASSIGN
OR OFFER TO ASSIGN RIGHTS IN INVENTION TO EMPLOYER.

(a)  Any provision in an employment agreement which provides that an employee
shall assign, or offer to assign, any of his or her rights in an invention to
his or her employer shall not apply to an invention that the employee developed
entirely on his or her own time without using the employer's equipment,
supplies, facilities, or trade secret information except for those inventions
that either:

     (1)  Relate at the time of conception or reduction to practice of the
invention to the employer's business, or actual or demonstrably anticipated
research or development of the employer.

     (2)  Result from any work performed by the employee for the employer.

(b)  To the extent a provision in an employment agreement purports to require an
employee to assign an invention otherwise excluded from being required to be
assigned under subdivision (a), the provision is against the public policy of
this state and is unenforceable.<PAGE>

                                                                EXHIBIT 10.16
                              CONSULTING AGREEMENT

Agreement ("AGREEMENT") dated 1 May, 1999 between Dr. Hana Berger Moran
("CONSULTANT") and BioMedlcines, Inc. ("BIOMEDICINES"), a Delaware corporation
having an address for purposes of this AGREEMENT at 1301 Marina Village Parkway,
Suite 200. Alameda, CA, 94501.

BIOMEDICINES and CONSULTANT (each a party ["PARTY"] to the AGREEMENT) intend to
establish a consulting relationship and each PARTY has therefore entered into
this AGREEMENT in order to define the terms of the consulting relationship.

WHEREAS, CONSULTANT is knowledgeable in developmental and regulatory matters of
importance to the advancement of the business of BIOMEDICINES; and

WHEREAS, BIOMEDICINES desires that it be able to utilize CONSULTANT's expertise
in advancing its drug development programs and business development activities;

NOW THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth the PARTIES hereby agree as follows:

1.   CONSULTANT ACTIVITIES

BIOMEDICINES agrees to contract with CONSULTANT for the provision of the
following services by CONSULTANT to BIOMEDICINES:

-    creation and execution of drug development and regulatory strategies for
     current or new drugs

-    preparation of drug development and regulatory documentation or reports for
     regulatory authorities in one or more countries or geographic areas

-    preparation for and the conduct of meetings with regulatory authorities
     worldwide

-    advising and assisting the company with respect to establishing, monitoring
     and complying with the requirements of current Good Manufacturing
     Practices, Good Laboratories Practices, and Good Clinical Practices
     worldwide

-    advising BIOMEDICINES with respect to the worldwide harmonization of
     regulatory guidelines

-    assisting BIOMEDICINES in becoming and remaining knowledgeable with respect
     to current regulatory guidelines, particularly with regard to the U.S. Food
     and Drug Administration

-    preparing for, attending and participating in project team meetings

-    evaluating new product candidates from developmental and regulatory
     perspectives

-    other such drug or business development activities for which the
     CONSULTANT's services are requested from time to time and which are
     otherwise mutually agreed.

CONSULTANT and BIOMEDICINES agree that services described above shall be
rendered in a manner, place and timeframe reasonably and mutually agreed by the
PARTIES.

                                       1.

<PAGE>

BIOMEDICINES agrees that payment to CONSULTANT for requested services shall be
made in accordance with the following schedule:

A maximal daily fee of two thousand dollars ($2,000.00) will be paid for each
full day of consultations provided to BIOMEDICINES for services physically
rendered in the North American continent, adjusted pro rata (i.e.,
$250.00/hour).

A maximal daily fee of two thousand eight hundred dollars ($2,800.00) will be
paid for each full day of consultations provided to BIOMEDICINES for services
physically rendered outside of the North American continent, adjusted pro rata
(i.e., $350.00/hour).

CONSULTANT will also receive compensation at one-half the stated standard hourly
rates for the actual hours devoted to air travel on behalf of BIOMEDICINES. Such
compensation during air travel will, therefore, not exceed one thousand dollars
($1.000.00) per day for travel originating and terminating within the North
American continent or fourteen hundred dollars ($1,400.00) per day for travel
originating or terminating outside the North American continent. In addition,
however, such compensation shall be due if and only if such hours of air travel
are devoted to BIOMEDICINES-related activities such as preparing for
BIOMEDICINES' meetings and the like. Moreover, in no event shall the sum of
consulting- and travel-related fees in any one day exceed the daily maxima of
either $2,000.00 or $2,800.00, as appropriate.

BIOMEDICINES will provide reimbursement for reasonable expenses (air fare, auto
rental or public transport, meals, telephone or fax charges and the like) for
requested travel. BIOMEDICINES will also provide reimbursement for other,
reasonable out-of-pocket expenses as negotiated on a case-by-case basis with the
BIOMEDICINES.

Air travel is to be made with economy (coach) class fares unless CONSULTANT
attends meetings outside of the North American continent on behalf of
BIOMEDICINES in which case business class airfare will be authorized.

In the event that CONSULTANT provides consulting activities to BIOMEDICINES and
to another client during the course of business travel on behalf of
BIOMEDICINES, CONSULTANT also agrees to bill BIOMEDICINES reasonably, equitably
and pro rata for all such travel-related expenses.

CONSULTANT hereby represents that there are no binding agreements to which the
CONSULTANT is a party or by which the CONSULTANT is bound, forbidding or
restricting CONSULTANT's activities herein. In addition, the CONSULTANT consents
to being named as a scientific or regulatory advisor in various reports,
brochures or other documents produced by or on behalf of BIOMEDICINES, including
any and all documents filed with the Food and Drug Administration, other similar
health authorities, the Securities and Exchange Commission or other similar
governmental authorities.

CONSULTANT agrees to keep and regularly submit suitably detailed records of
activities, time and expenses. As appropriate, the specific BIOMEDICINES project
will be identified, the consulting services performed, the date on which said
services were performed, the time required to perform said services, and the
details of any expenses incurred will appear in each such record

                                       2.
<PAGE>

of activities, time, and expenses. Expense items costing in excess of $25.00
should be accompanied by receipts.

CONSULTANT also agrees to meet or otherwise communicate, as reasonably requested
by BIOMEDICINES, as least bi-weekly with a designated representative of
BIOMEDICINES to review and to discuss past and/or future consulting activities.

BIOMEDICINES is free to terminate the AGREEMENT at any time for any reason by
providing thirty (30) days' written notice to CONSULTANT. BIOMEDICINES agrees to
pay for any work completed by CONSULTANT on behalf of BIOMEDICINES but not yet
paid prior to such termination.

CONSULTANT is free to terminate the AGREEMENT with thirty (30) days' written
notice. CONSULTANT agrees to deliver all work previously committed by CONSULTANT
and all opinions or other work for which any payment has already been received.

2.   CONFIDENTIAL INFORMATION

A separate confidentiality agreement has been executed and is incorporated
herein.

3.   OWNERSHIP OF INVENTIONS

In consideration for the compensation paid to CONSULTANT by BIOMEDICINES as
described in Section 1, CONSULTANT hereby assigns to BIOMEDICINES all
CONSULTANT's rights, title and interest in all inventions which arise from
CONSULTANT's activities for BIOMEDICINES hereunder, and agrees to cooperate
fully in the prosecution of any patent application resulting from any such
invention, at the expense of BIOMEDICINES, which cooperation shall include
executing any necessary documents in connection therewith. CONSULTANT shall be
paid the standard fees described herein for such activities on behalf of
BIOMEDICINES. CONSULTANT further acknowledges that potentially patentable
concepts may be disclosed to CONSULTANT by BIOMEDICINES during the course of the
AGREEMENT and that such disclosure is confidential as defined in the existing
confidentiality agreement.

4.   ADVISORY ROLE AND INDEMNIFICATION

BIOMEDICINES acknowledges that unless otherwise specifically agreed CONSULTANT's
role is advisory in nature and that BIOMEDICINES remains free to accept or
reject CONSULTANT's recommendations or advice. BIOMEDICINES also remains free to
use or not to use any document(s) prepared by CONSULTANT on behalf of
BIOMEDICINES. BIOMEDICINES accepts full responsibility for accepting
CONSULTANT's advice or for using any documents prepared by CONSULTANT.

Furthermore, BIOMEDICINES will indemnify and defend CONSULTANT against any and
all actions against CONSULTANT that arise directly or indirectly from
CONSULTANT's activities on behalf of BIOMEDICINES. provided, however, that such
indemnification shall not extend to any illegal or unlawful actions by
CONSULTANT.

                                       3.
<PAGE>

Notwithstanding the foregoing of this Section 4, however, in the event that
BIOMEDICINES shall subsequently request CONSULTANT to serve as an agent
("AGENT") of BIOMEDICINES and CONSULTANT shall so agree. CONSULTANT shall be
indemnified and entitled to the same privileges and protection as would be
afforded a BIOMEDICINES employee performing those actions undertaken by
CONSULTANT when acting as AGENT for BIOMEDICINES.

5.   MISCELLANEOUS

     (a)  This AGREEMENT supersedes all prior consulting agreements, written or
oral, between the parties hereto relating to consulting activities on behalf of
BIOMEDICINES. This AGREEMENT does not supersede the separate or, confidentiality
agreement. This AGREEMENT may not be modified, changes or discharged, in whole
or in part, except by a written agreement signed by both parties.

     (b)  This AGREEMENT will be binding upon and inure to the benefit of the
parties and their respective heirs, successors and assigns.

     (c)  This AGREEMENT shall be construed and interpreted in accordance with
the laws of the State of California for contracts entered into and performed
solely in California.

     (d)  The provisions of this AGREEMENT are necessary for the protection of
the business interests and good will of the parties and are considered by the
parties to be reasonable for such purpose. The CONSULTANT agrees that any breach
of this AGREEMENT will cause the BIOMEDICINES substantial and irreparable harm.
and therefore, in the event of any such breach, in addition to other remedies
which may be available. the BIOMEDICINES shall have the right to seek specific
performance and other injunctive and equitable relief.

     (e)  The provisions of this AGREEMENT relating to confidentiality,
assignment of inventions, anti cooperation during patent prosecution shall
survive any termination or expiration hereof.

EXECUTED as of the date written above.

for BIOMEDICINES                                for CONSULTANT

/s/ Brian G. Atwood                             /s/ Hana Berger Moran
---------------------------                     -----------------------------
signature                                       signature

Brian G. Atwood                                 Hana Berger Moran, Ph.D.
Chairman

                                                SSN:   ###-##-####

                                                Address:  55 Orinda View Rd.,
                                                Orinda, CA 94563
                                                Telephone:  925-299-1963
                                                Fax: 925-299-0349

                                       4.
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]